The FDA has approved the GABA_A receptor modulator brexanolone (Zulresso – Sage Therapeutics) for IV treatment of postpartum depression (PPD). Brexanolone is the first drug to be approved by the FDA for this indication.

Postpartum depression may affect up to 20% of women after childbirth. It has been associated with impaired mother-infant bonding and with adverse effects on the cognitive, behavioral, and emotional development of the child.

Selective serotonin reuptake inhibitors (SSRIs) are generally used for initial treatment of moderate to severe PPD, but data on their efficacy for this indication are mixed and maximal effects are only achieved after several weeks of treatment. Serotonin-norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants have also been used, but data on their efficacy are limited. Electroconvulsive therapy is rapid-acting and has been reported to be effective for treatment of refractory PPD.¹

FDA批准了GABA _A受体调节剂布雷索龙（Zulresso – Sage Therapeutics）用于产后抑郁症（PPD）的IV治疗。布雷沙洛酮是FDA批准的第一种用于该适应症的药物。

产后抑郁症可能会影响到分娩后多达20％的女性。它与母婴结合力受损以及对儿童的认知，行为和情感发展产生不利影响有关。

选择性5-羟色胺再摄取抑制剂（SSRI）通常用于中度至重度PPD的初始治疗，但有关此适应症功效的数据参差不齐，只有在治疗数周后才能达到最大效果。还使用了5-羟色胺去甲肾上腺素再摄取抑制剂（SNRIs）和三环抗抑郁药，但有关其功效的数据有限。电抽搐疗法是快速起效的，据报道对治疗难治性PPD有效。^1个